Fractyl Health

GUTS

Market cap $90.3M

Fractyl Health, Inc. (GUTS) Q4 2025 Earnings Call Transcript

BURLINGTON, Mass., March 17, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company), a clinical stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes, today announced that it will report financial results for the fourth quarter and full year 2025 and provide business updates on Tuesday, March 24, 2026, at 4:30 p.m.

Fractyl Health, Inc. (GUTS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Topline 6-month pivotal data expected in early Q4 2026 with potential FDA marketing application submission expected in late Q4 2026 Company reiterates cash runway guidance into early 2027, beyond anticipated pivotal data readout BURLINGTON, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl), a clinical stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes, today announced completion of participant randomization in its REMAIN-1 Pivotal Cohort, a double-blind, sham-controlled study evaluating Revita ® for weight maintenance following GLP-1 therapy discontinuation.

The heavy selling pressure might have exhausted for Fractyl Health, Inc. (GUTS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Fractyl Health offers a buy-the-dip opportunity after an overreaction to underwhelming 6-month pilot data for its Revita device. Revita's pivotal Phase 3 obesity trial is well-funded, with topline results expected in 2H 2026 and a low statistical bar for success. Weight regain in the Revita arm was driven by a single site; excluding it, results align with prior positive data, supporting optimism for pivotal readout.

LOS ANGELES--(BUSINESS WIRE)--Fractyl Health, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – GUTS.

LOS ANGELES--(BUSINESS WIRE)--Fractyl Health, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – GUTS.

Fractyl Health Inc. (NASDAQ: GUTS) stock plunged on Thursday after the company hinted at a change in its U.S. regulatory strategy for Revita.

Fractyl Health, Inc. (GUTS) Discusses REMAIN-1 Midpoint Cohort Results on Revita for Weight Maintenance After GLP-1 Discontinuation Transcript